ResearcherLanzhou UniversityActive in the last 2 years

Wence Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9587-5798; OpenAlex author ID A5075039924. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2025: 1 paper

Papers 1

Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis Last author DOI 10.21203/rs.3.rs-5324510/v2 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chunlu Dong · 1 shared paper, 2025 · strength 0.27
- Paper Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis DOI 10.21203/rs.3.rs-5324510/v2 ↗
Fangfang Han · 1 shared paper, 2025 · strength 0.27
- Paper Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis DOI 10.21203/rs.3.rs-5324510/v2 ↗
Huaqing Shi · 1 shared paper, 2025 · strength 0.27
- Paper Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis DOI 10.21203/rs.3.rs-5324510/v2 ↗
Yan Du · 1 shared paper, 2025 · strength 0.27
- Paper Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis DOI 10.21203/rs.3.rs-5324510/v2 ↗
Zhou Chen · 1 shared paper, 2025 · strength 0.27
- Paper Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis DOI 10.21203/rs.3.rs-5324510/v2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.